Risk Assessments and Reimbursement: A novel solution to protect lab revenue while supporting patient care

In today’s high-scrutiny environment, clinical reference laboratories and physician-owned labs face a difficult balancing act: how to deliver high-quality drug testing that supports effective patient care, while minimizing compliance risk and protecting revenue in light of many payers tying frequency of testing limits to opioid risk assessment and stratification levels.

Our latest webinar brings together a panel of regulatory and RCM experts to share practical strategies for reducing your liability to payer audits, without sacrificing legitimate reimbursement opportunities. We will uncover how common missteps in opioid risk assessment and documentation can put your organization at risk, and how to correct course with tools and education that safeguard both compliance and cash flow.

You’ll learn:

• Why overreliance on opioid risk screening tools can lead to compliance violations and lost revenue.
• How Medicare and commercial payers are interpreting “medical necessity” for drug testing and how those interpretations impact reimbursement.
• The downstream effects of poor documentation on patient safety, legal exposure, and lab finances.
• How to implement a comprehensive opioid risk assessment approach that meets payer criteria and enhances defensible billing, while improving patient care.
• Best practices for provider education that protect ordering clinicians, patients, and laboratories.